May 27, 2026-LDEBIO receives China NMPA Class III approval for AIMLAM (CLIA) – the world’s first LAM-based urine test for ALL populations (HIV+ and HIV‑).
· Non‑invasive urine sample
· Chemiluminescence platform – fast & stable
· For active TB (pulmonary & extrapulmonary)
· Previously listed in WHO TB reports (2023, 2024)
A major step forward for accessible TB diagnosis.
#EndTB #TBdiagnostics #LAM #Innovation #LDEBIO
